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Background:  The  AIDS  epidemic  in  Southern  Brazil  has  unique  features,  showing  co-circulation  of  HIV-
1  subtypes  C,  B  and  recombinant  forms.  Florianópolis  has the  second  highest  AIDS  incidence  among
Brazilian  capitals,  but  limited  information  is  available  about  HIV  molecular  epidemiology  and  prevalence
of  primary  drug  resistance.
Objectives:  To  investigate  the  molecular  epidemiology  of  HIV-1  in Florianópolis  and  to  describe  the
prevalence  of  primary  HIV-1  drug  resistance  mutations  (DMRs).
Study  design:  Epidemiological  and  clinical  data  from  82  untreated  patients  from  Florianópolis
(2008–2009)  were  analyzed.  The  HIV-1  subtype  at envelope,  protease,  reverse  transcriptase  and  inte-
grase  regions  were  determined  by  phylogenetic  and  bootscaning  analyses  and  the  drug  resistance  proﬁle
were  analyzed  at  the Stanford  HIV  Drug  Resistance  Database.
Results:  The  most  frequent  HIV-1  genetic  form  was  subtype  C (65.8%)  followed  by mosaics  BC (18.3%),
subtype  B (13.4%),  subtype  F1 (1.2%)  and  BCF1  recombinant  (1.2%).  HIV-1  subtype  C and  BC  recombinants
were  much  more  frequent  in  the  heterosexual  exposure  category,  whereas  subtype  B  was  more  common
in the  MSM  exposure  category.  DRMs  were  seen  in  11%  of  the  sequences,  2.4%  of them  were  related  to
PI, 5%  to NRTI,  3.6%  to NNRTI  and  1.2%  was  related  to  INTI.
Conclusions:  The  present  study  conﬁrms  the  high  prevalence  of  subtype  C and  BC recombinants  in Santa
Catarina  State  and  revealed  a signiﬁcant  difference  in  the  subtype  distribution  among  distinct  virus expo-
sure  categories.  This  study  also  shows  a  relative  high  prevalence  of  protease/reverse  transcriptase  primary
drug  resistance  mutations  and  corroborates  the usefulness  of the  integrase  inhibitors  in southern  Brazil.. Background
The HIV/AIDS pandemic has a major impact in Brazil, being
he most affected Country in Latin America with over 600,000
eople infected.1 The Brazilian HIV-1 epidemic can be divided
n two distinct scenarios. While subtype B prevails in most of
he Country, with a secondary occurrence of subtype F1 and BF1
Abbreviations: AIDS, acquired immune deﬁciency syndrome; ARV, antiretro-
iral; CPR, calibrated population resistance tool; CRF, circulating recombinant
orm; DRMs, drug resistance mutations; INT, integrase; INTI, integrase inhibitors;
IV, human immunodeﬁciency virus; MSM,  men  who have sex with men; NJ,
eighbor-joining; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI,
ucleoside reverse transcriptase inhibitors; PCR, polymerase chain reaction; PI, pro-
ease inhibitors; PR, protease; RT, reverse transcriptase; URF, unique recombinant
orm.
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recombinants,2–9 Southern Brazil presents a distinct pattern with
high frequency of subtypes C, B and BC recombinants, following a
lower proportion of subtype F1 and BF1 recombinants,10–17 com-
prising 19% of the infected individuals in the Country.
The universal access of Brazilian HIV-positive patients to free-
of-cost licensed antiretroviral drugs has substantially reduced the
AIDS-related mortality.1 The effectiveness of antiretroviral ther-
apy, however, may  be limited by the increasing of resistance to
antiretroviral drugs and by transmission of such drug-resistant
viruses to drug-naïve patients. National surveys suggest that pri-
mary HIV resistance in Brazil is generally low, ranging from 6% to
8%.2,18,19 However, very high prevalence of HIV primary drug resis-
tance (18–37%) were observed in some localities, such as the City
of Santos (Southeastern region)20,21 and the State of Bahia (North-
Open access under the Elsevier OA license.eastern region),22 indicating important differences across country
regions.
Most of the molecular epidemiology studies on HIV in the South-
ern region were carried out in the State of Rio Grande do Sul, but
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Rig. 1. Geographical location of Florianópolis and frequency of HIV-1 subtypes at 
atarina (SC) and the metropolitan region of Florianópolis. (b) HIV-1 subtypes were
imited data concerning the prevalence of HIV-1 subtypes and HIV
rimary drug resistance in the other southern states (Santa Catarina
nd Paraná) is available. Noteworthy, Santa Catarina State ranks
hird on AIDS incidence rate in Brazil (29.6 new cases per 100,000
nhabitants in 2008), while its capital, Florianópolis city, occupies
he second position in the ranking of capitals (53.7 new cases per
00,000 inhabitants in 2008).1 Moreover, Florianópolis city is a very
mportant tourist pole in Southern Brazil, receiving people from
ther South American countries, mainly Argentina and Uruguay,
hich could have implications on the distribution of HIV subtypes
nd recombinant forms.
. Objectives
This study describes the HIV-1 genetic diversity among different
xposure categories and the prevalence of HIV primary drug resis-
ance mutations based on sequence analyses of protease, reverse
ranscriptase, integrase and envelope genes among naïve patients
rom Florianópolis metropolitan area, Santa Catarina, Brazil.
ig. 2. Phylogenetic analysis of CRF31 BC-like sequences. (a) Neighbor-joining phylogenet
ike  sequences from Santa Catarina (black diamonds) and subtype reference sequences. Rel
above  70%) are shown. (b) Bootscaning patterns corresponding to a CRF31 BC reference 
eference sequences were extracted from HIV Los Alamos Database.fferent genomic regions analyzed. (a) Map of Brazil highlighting the state of Santa
mined by phylogenetic and bootscaning analyses, as described in Section 3.
3. Study design
3.1. Patients
Blood samples were collected from 82 HIV-infected patients
followed up at Hospital Homero de Miranda Gomes located in
metropolitan region of Florianópolis, Santa Catarina, Brazil. The
individuals were selected from May-2008 to February-2009 and
inclusion criteria included age over 18-year old, no sign or symptom
of AIDS and no previous antiretroviral therapy. The Universidade
Federal de Santa Catarina Ethics Committee approved the study
and informed consent was  obtained from all volunteers.
3.2. Extraction, ampliﬁcation and sequencing of HIV-1 DNA
PBMC was  isolated from 4 ml  of blood by the Histopaque
(Sigma–Aldrich, St. Louis, MO,  USA) density gradient method
and genomic DNA was  extracted using a QIAmpl Blood Kit
(Qiagen Inc., Chatswoth, CA, USA). HIV-1 protease (PR), reverse
transcriptase (RT), integrase (INT) and envelope (env) genes were
ic tree of PR/RT region (2316–3316 nt relative to HXB2), including only the CRF31 BC-
iability was  tested with 1000 replicates bootstrapped, values considering signiﬁcant
sequence and the three sequences from Santa Catarina classiﬁed as CRF31 BC like.
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Fig. 3. Schematic drawing showing breakpoint pattern of the mosaics viruses found in the study. Breakpoint positions were obtained using Simplot 3.5.1 and numbered
according to HXB2 reference. The pol (PR/RT, INT) and env (gp120-C2V3) genes are colored according to the subtype: subtype B is red, subtype C is blue and subtype F1 is
represented in green. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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Table 1
General characteristics of HIV-1 infected individuals according to the HIV-1 subtypes.
Total (n = 82) Subtype C (n = 54) Subtype B (n = 11) BC mosaic (n = 15)
Mean age (years) 37.8 ± 10 39 ± 9.2 31.3 ± 9.3 37 ± 11
Sex  (%)
Male 40 (48.8%) 23 (43%) 9 (82%) 7 (46.7%)
Female  42 (51.2%) 31 (57%) 2 (18%) 8 (53.3%)
Mean  diagnostic year 2004 ± 3.8 2004 ± 4.3 2005 ± 2.1 2005 ± 2.7
Exposure categories
Heterosexual 58 (70.6%) 41 (76%) 3 (27.3%) 12 (80%)
MSM  18 (22%) 9 (16.5%) 8 (72.7%) 1 (6.6%)
Injection drug user 4 (5%) 3 (5.5%) – 1 (6.6%)
Unknown 2 (2.4%) 1 (2%) – 1 (6.6%)
Mean  CD4 T-cell count 513 ± 312 492 ± 269 563 ± 429 522 ± 366
.1 ± 0.
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eMean  viral load (log10 copies/ml) 4.1 ± 0.8 4
alues are expressed ± standard deviation of the mean.
mpliﬁed by a nested-PCR as described elsewhere.23–25 Puriﬁed
roducts were sequenced using MegaBace® 1000 DNA Analysis
ystem (GE Healthcare). Sequences were visually inspected and
ssembled by using SeqMan software, LaserGene package (DNAS-
AR, Madison, WI,  USA). Sequences were submitted to GeneBank
nder accession numbers JF773818-JF774062.
.3. HIV-1 subtype classiﬁcation
Nucleotide sequences were aligned by using Clustal X
rogram.26 The two pol gene alignments cover almost whole PR
nd part of RT (nucleotides 2316–3316 relative to HXB2) and
hole INT (nucleotides 4230–5096 relative to HXB2), while the env
ene alignment covers gp120-C2V3 region (nucleotides 6905–7288
elative to HXB2). Phylogenetic analyses were performed by the
eighbor-Joining (NJ) algorithm using the Tamura-Nei nucleotide
ubstitution model,27 in 1000 bootstrap replicates, as implemented
n MEGA v4 program.28 Analysis of recombination was  performed
y bootscaning analysis (sliding window of 250 bp, incremental
teps of 10 bases, and the Kimura two-parameter model29) using
implot 3.5.1 software.30 Bootstrap support was calculated based
n 100 re-samplings.
.4. Resistance analysis
Drug-resistance mutations (DRMs) proﬁle and antiretrovi-
al (ARV) susceptibility were inferred by submitting the PR/RT
equences to the Calibrated Population Resistance Tool (CPR) (ver-
ion 5.0 beta; available at http://cpr.stanford.edu/cpr/servlet/CPR)
nd the INT sequences to the Stanford HIV Resistance Database
http://hivdb.stanford.edu/). The CPR program provides a standard
able 2
rimary drug resistance mutations associated to protease, reverse transcriptase and integ
Sample Pol subtype PI resistance
mutations
NRTI resistance
mutations
NNRTI
resistance
mutations
BR10SC06 C 
BR10SC07 C N88D 
BR10SC29 B K219Q 
BR10SC42 C M46I 
BR10SC46 B V75M 
BR10SC47 C K101E, V10
G190A, M2
BR10SC50 C M41L, T215C 
BR10SC107 C M41L G190A 
BR10SC131 C K103N 
I, protease inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nu
ZT,  zidovudine; DDI, didanosine; DLV, delavirdine; d4T, stavudine; EFV, efavirenz; ETR,
lvitegravir.8 4.4 ± 0.9 3.9 ± 0.7
approach to estimating the prevalence of transmitted HIV drug
resistance using population-sampled sequence data and disregard
natural occurring polymorphisms and mutations occurring in a fre-
quency higher than 0.5% in untreated subjects.31,32
3.5. Statistical analysis
The Chi-squared test was  employed to evaluate possible associ-
ation of HIV-1 subtype with demographic, exposure category and
clinical variables. A p value <0.05 was  considered signiﬁcant.
4. Results
Out of 82 HIV-1 isolates analyzed at the PR/RT, INT and env
regions, 54 (65.8%) were classiﬁed as subtype C, 15 (18.3%) as B/C
inter-subtype recombinants, 11 (13.5%) as subtype B, one (1.2%) as
subtype F1 and one (1.2%) as B/C/F mosaic form (Fig. 1). Three (3.6%)
BC recombinant sequences displayed a CRF31 BC-like recombi-
nation proﬁle at PR/RT and clustered among CRF31 BC reference
sequences in the pol (PR/RT) NJ tree (Fig. 2). One of these sequences
(BR10SC93) displayed one additional B/C recombination point at
INT and was  classiﬁed as a unique recombinant form (URF), as well
as the remaining inter-subtype recombinant sequences (Fig. 3).
Table 1 summarizes the demographic characteristics, exposure
category, clinical and genetic HIV subtype data of the 82 patients
analyzed. Forty (48.8%) patients were males and 42 (51.2%) were
females, with a mean age of 37.8 years. The major exposure cat-
egory was  heterosexual (70.6%), followed by men who have sex
with men  (MSM)  (22%) and injection drug users (5%). The herein
presented data shows a highly signiﬁcant association (p < 0.001)
between exposure category and HIV-1 subtype. Eighty percent of
rase genes among treatment naïve patients.
INTI resistance
mutations
Resistance proﬁle
Low Intermediate High
S147R + E138A RAL, ELV
NFV
AZT
NFV
DDI d4T
6M,
30L
ETR DLV, EFV, NVP
ABC, DDI, TDF AZT, d4T
AZT, d4T, ETR EFV NVP
DLV, EFV, NVP
cleoside reverse transcriptase inhibitors; INTI, integrase inhibitors; ABC, abacavir;
 etravirine; NFV, nelﬁnavir; NVP, nevirapine, TDF, tenofovir; RAL, raltegravir; ELV,
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C recombinants (URFs BC + CRF31 BC-like) and 76% of subtype C
equences were ampliﬁed from individuals of the heterosexual
xposure category, whereas 73% of subtype B sequences were in
SM  exposure category (Table 1). Subtype B sequences represent
4% of viruses circulating in the MSM  population, but only 5% of
iruses circulating among heterosexual or female populations. No
tatistically signiﬁcant differences at CD4 T cell count, RNA viral
oad or mean age were found among HIV-1 subtypes.
Among 82 HIV-1 pol sequences obtained from drug naïve
atients, the presence of at least one DRM was  observed in 9
11.0%) patients (Table 2). DRMs to protease inhibitors (PI) were
bserved in two (2.4%) patients. Polymorphisms and mutations
t protease secondary codons were seen in 17 (20.7%) sequences,
eing L10I/V and T74S the most frequently found (data not shown).
utations related with resistance to nucleoside reverse transcrip-
ase inhibitors (NRTI) were observed in four (5%) sequences, and
41L was the most common. DRMs to non-nucleoside reverse
ranscriptase inhibitors (NNRTI) were observed in three (3.6%) of
he sequences analyzed, and G190A was the most common. Resis-
ance to integrase inhibitors (INTI) was observed in only one (1.2%)
atient who displayed the resistance mutations S147R and E138A,
hich confer a low-level of resistance to raltegravir and elvite-
ravir. Minor drug resistance mutations at INT were observed in 11
13.5%) sequences, being V151I the most frequently found, espe-
ially among subtype B samples (data not shown).
One patient showed DRMs to more than one class of antiretro-
iral drugs. Among the 11 HIV-1 subtype B pol sequences, two
18%) displayed DRM, whereas among the 56 HIV-1 subtype C pol
equences, eight (14.3%) showed at least one DRM. Nevertheless,
hat difference was not signiﬁcant (p > 0.05) and no correlation
etween resistance mutations and HIV-1 subtypes at pol was found.
. Discussion
The present work describes a high prevalence (65.8%) of HIV-1
ubtype C in Florianópolis metropolitan area, consistent with two
ecent studies which described a subtype C prevalence of 64% and
9% in other cities of Santa Catarina State.13,16 This conﬁrms the
igher prevalence of subtype C in Santa Catarina when compared
ith other Southern Brazilian states: 20–30% in Paraná15,17 and
7–42% in Rio Grande do Sul.12,13 The molecular epidemiology sce-
ario of Florianópolis also shows a high frequency (18.3%) of BC
ecombinants. Two out of 15 BC recombinant sequences identiﬁed
howed a CRF31 BC-like recombinant pattern at pol (PR/RT/INT)
nd env genes, reinforcing that HIV-1 CRF31 BC circulates at low
requency in Santa Catarina, consistent with previous studies.13,16
ne URF BC identiﬁed herein displayed a CRF31 BC-like pattern
t PR/RT, but one additional B/C breakpoint at INT, while others
RFs BC displayed one coincident recombination breakpoint with
RF31 BC at PR/RT, but larger subtype B fragments. These variants
ay  be second generation recombinants originated from recombi-
ation between CRF31 BC and subtype B strains, as was  recently
escribed in Rio Grande do Sul.25 Although Florianópolis receives a
ery important number of tourists from Argentina and Uruguay,
e found no evidence of circulation of BF recombinant forms
ommonly observed in those countries (such as CRF12 BF and
RF38 BF)33, pointing to a minor impact of international tourism
n the HIV molecular epidemiology scenario of Florianópolis.
A signiﬁcant association was observed between HIV-1 subtype
nd exposure category, suggesting that two independent epidemics
re occurring in Santa Catarina. It seems that HIV-1 subtype C
roke up the barriers that separate the exposure categories and
irculates at high prevalence within both heterosexual (70.7%) and
SM  (50%) groups. By contrast, HIV-1 subtype B circulates at high
revalence within MSM  group (44.4%), but not within heterosexualirology 51 (2011) 186– 191
group (5.2%). On the other hand, the high prevalence of URFs BC
reﬂects frequent episodes of coinfections and/or superinfections in
the studied population. The connection between subtypes B and C
epidemics seems to be more frequent in heterosexual population,
but further investigations with a higher number of MSM  patients
are necessary to conﬁrm this observation.
Comparison of the HIV-1 env gene results from the current work
with those obtained in a previous study performed in the same
area14 revealed a signiﬁcant increase in the proportion of subtype
C at heterosexual population from 56% in 2004 to 83% in 2008/2009;
while the proportion of env subtype B decreases from 38% to only
15% in the same period. This result suggests a faster spread of sub-
type C than subtype B among heterosexual population over last
years in Santa Catarina. These observations may  reveal a differ-
ent efﬁcacy of homosexual/heterosexual transmission of subtypes
B and C, or may  reﬂect different entries and dissemination networks
of these subtypes in Santa Catarina. The high proportion of subtype
B among females in Rio Grande do Sul and Paraná (38–42%),12,17
and the recent expansion of subtype C among MSM  in São Paulo
(Brazil),34 strongly favor the second hypothesis.
Our ﬁndings indicate a prevalence of PR/RT primary DRMs (10%)
higher than the national average (6–8%),2,18,19 although lower than
those described in other Brazilian regions (18–37%).20–22 Notwith-
standing, the prevalence of primary resistance presented herein
may  be underestimated due mostly selected patients were chronic
cases (>12 months since HIV infection), and HIV tends to return
to wild type over time without ARV selective pressure as DRMs
reduce the viral ﬁtness.35 We  also observed one patient with low-
level resistance to INTI. Such resistance mutations, however, should
not be considered a case of transmitted resistance since the diag-
nostic date of that patient was 2002, several years before the
introduction of Raltegravir in Brazil (2009). Those mutations prob-
ably reﬂect rare substitutions in the integrase gene as described
elsewhere.36–38 These results encourage the use of this new drug
in the treatment of AIDS patients in Southern Brazil.
In conclusion, our study indicates an increase of HIV-1 sub-
type C prevalence in the metropolitan area of Florianópolis with
a signiﬁcantly association between virus subtypes and exposure
categories. The Southern region shows the highest incidence of
HIV-1 infections in the country, which combined with the increas-
ing contribution of HIV-1 infections among heterosexuals, might
explain the expansion of subtype C in the Brazilian epidemic. This
combination makes southern Brazil an interesting site for devel-
opment of health innovations and vaccine trials.39 The presented
work also describes a prevalence of DRMs above the national aver-
age, pointing to the importance of sustained surveillance studies in
this region.
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